VTGN News & Events

Vistagen announced the topline results of the PALISADE-4 Phase 3 trial of intranasal fasedienol for the acute treatment of social anxiety disorder. In the overall trial population, fasedienol did not achieve its primary endpoint, as measured by the least squares mean change from baseline on the SUDS score for fasedienol compared with placebo, with a difference in the LS means of 1.9. There was no treatment difference between fasedienol and placebo for the secondary endpoints. Favorable safety and tolerability data of fasedienol were consistent with previous placebo-controlled clinical trials.

Vistagen announced the appointment of Angel Angelov, MD, MBA, as Chief Medical Officer, CMO, effective May 18, 2026. Dr. Angelov most recently served as CMO at Theranica

Vistagen announced preliminary positive data from the ongoing open-label extension portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. In a recent analysis of subjects who elected to participate in the OLE portion of PALISADE-3, administration of 3.2 microgram of fasedienol - taken as needed, up to six times per day in real-world, anxiety-provoking situations in daily life for up to 12 months - has been well-tolerated, with no new drug-related safety findings or trends identified. Exploratory efficacy data over the first four months of treatment demonstrated a clinically relevant improvement over time on both the clinician-administered Liebowitz Social Anxiety Scale and the Social Phobia Inventory. "Social anxiety disorder surfaces in the everyday moments of people's lives," said Shawn Singh, President and Chief Executive Officer of Vistagen. "Among our core goals is giving patients the ability to manage their anxiety in the daily life situations that matter most to them. We're continually encouraged by the improvements observed over time when patients in our open-label studies self-administer fasedienol as they feel it's needed."